Ustekinumab misses primary endpoint in atopic dermatitis

SCOTTSDALE, ARIZ. – Treatment with ustekinumab did not result in significant improvements in atopic dermatitis after 16 weeks, compared with placebo in a phase II study of adults with moderate to severe atopic dermatitis, Dr. Patrick Brunner reported at the annual meeting of the Society for...
Source: Skin and Allergy News - Category: Dermatology Source Type: news